ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process (2020)
Fonte: Frontiers in Endocrinology. Unidade: ICB
Assuntos: BIOLOGIA CELULAR, INSULINA, DIABETES MELLITUS, CAMUNDONGOS, CÁLCIO, GLICOSE, METABOLISMO ENERGÉTICO, MODELOS ANIMAIS DE DOENÇAS
ABNT
FERREIRA, Sandra M. et al. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process. Frontiers in Endocrinology, v. 11, p. 9 , 2020Tradução . . Disponível em: https://doi.org/10.3389/fendo.2020.599165. Acesso em: 11 nov. 2024.APA
Ferreira, S. M., Costa Júnior, J. M., Kurauti, M. A., Leite, N. C., Ortis, F., Rezende, L. F., et al. (2020). ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process. Frontiers in Endocrinology, 11, 9 . doi:10.3389/fendo.2020.599165NLM
Ferreira SM, Costa Júnior JM, Kurauti MA, Leite NC, Ortis F, Rezende LF, Barbosa HC, Boschero AC, Santos GJ. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process [Internet]. Frontiers in Endocrinology. 2020 ; 11 9 .[citado 2024 nov. 11 ] Available from: https://doi.org/10.3389/fendo.2020.599165Vancouver
Ferreira SM, Costa Júnior JM, Kurauti MA, Leite NC, Ortis F, Rezende LF, Barbosa HC, Boschero AC, Santos GJ. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process [Internet]. Frontiers in Endocrinology. 2020 ; 11 9 .[citado 2024 nov. 11 ] Available from: https://doi.org/10.3389/fendo.2020.599165